Autoantibody to plasma fibrinopeptide A in a patient with a severe acquired haemorrhagic syndrome.
We describe a 50-year-old man with a severe acquired haemorrhagic syndrome. He had slightly prolonged clotting times using bovine thrombin, human thrombin and reptilase. His plasma contained a polyclonal IgG which interfered with the generation of fibrin monomers without inhibiting the aggregation of preformed monomers. The inhibitor delayed thrombin-induced fibrinopeptide A release. The IgG bound to insolubilized synthetic fibrinopeptide A (one binding site per molecule) and, with higher affinity, to fibrinogen (two binding sites per molecule). It did not bind to insolubilized fibrin monomers. The IgG did not impair the catalytic activity of thrombin toward a small synthetic substrate but inhibited the binding of thrombin to fibrinogen without binding to thrombin. The binding of the anti-fibrinopeptide A autoantibody to fibrinogen might have impaired thrombin-induced fibrinogen to fibrin conversion in vivo. This may have favoured the reported haemorrhagic syndrome which was associated with severe chronic renal insufficiency.
Gris
J C
JC
Laboratoire d'Hématologie, CHU, Nîmes, France.
Schved
J F
JF
Branger
B
B
Aguilar-Martinez
P
P
Vécina
F
F
Oulès
R
R
Sarlat
C
C
Fourcade
J
J
D001323:Autoantibodies / Q000032:analysis*; D001665:Binding Sites; D001778:Blood Coagulation Disorders / Q000276:immunology; D005337:Fibrin / Q000378:metabolism; D005340:Fibrinogen / Q000276:immunology / Q000378:metabolism; D005344:Fibrinopeptide A / Q000276:immunology*; D006470:Hemorrhage / Q000209:etiology*; D006801:Humans; D007074:Immunoglobulin G / Q000737:chemistry / Q000378:metabolism*; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D013917:Thrombin / Q000378:metabolism
D001323:Autoantibodies; D007074:Immunoglobulin G; D005344:Fibrinopeptide A; D005337:Fibrin; D005340:Fibrinogen; D013917:Thrombin